Infographic: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Eye (London) 2024-08, Vol.38 (Suppl 2), p.53-54
Hauptverfasser:	Wijesingha, Naomi, Sivaprasad, Sobha
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/3161/3175 692/700/565 692/700/565/1436 Age Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Humans Intravitreal Injections Laboratory Medicine Macular degeneration Macular Degeneration - drug therapy Medicine Medicine & Public Health Ophthalmology Pharmaceutical Sciences/Technology Surgery Surgical Oncology Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity Wet Macular Degeneration - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!